tag:blogger.com,1999:blog-7857054149675424609.post380780668638787510..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: RNAi Therapeutics More Relevant than EverDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger14125tag:blogger.com,1999:blog-7857054149675424609.post-15943814554431507482010-05-03T04:58:15.383+00:002010-05-03T04:58:15.383+00:00Interesting! Thanks for the heads up. I will take ...Interesting! Thanks for the heads up. I will take a look if I ever get free time from current project:<br /><br />http://www.sec.gov/Archives/edgar/data/1488039/000114420410016530/0001144204-10-016530-index.htmStevenQuayhttps://www.blogger.com/profile/16774112128798375734noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-32538371546120654692010-04-29T20:07:46.332+00:002010-04-29T20:07:46.332+00:00It is the fundamental LNA patent by Wengel:
EP 101...It is the fundamental LNA patent by Wengel:<br />EP 1015469 B1, BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES <br /><br />Santaris 53 patent families (mostly applications) are mostly directed to specific modification patterns, uses, sequences, i.e. more narrow patents. <br /><br />And many of these are having a tough time at the patent offices.SK1https://www.blogger.com/profile/12753110711303499342noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-15172361227019528752010-04-29T15:08:36.163+00:002010-04-29T15:08:36.163+00:00The Wengel patent estate consists of some 53 paten...The Wengel patent estate consists of some 53 patent families according to Santaris Pharma. Can you be more specific about which patent you are speaking of?StevenQuayhttps://www.blogger.com/profile/16774112128798375734noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-39297417687025766042010-04-29T14:01:20.093+00:002010-04-29T14:01:20.093+00:00In Europe, the Wengel patent has been revoked in o...In Europe, the Wengel patent has been revoked in opposition proceedings.SK1https://www.blogger.com/profile/12753110711303499342noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-51463061815640616712010-04-21T16:21:09.746+00:002010-04-21T16:21:09.746+00:00Dirk-
The ISIS "novel" analogues begin ...Dirk-<br /><br />The ISIS "novel" analogues begin with an LNA and then substitute one of the bridge -H bonds with an -R, where R is the 'signature' ISIS O-methyoxy-ethyl residue. I actually believe are they are anticipated by the Wengel issued patents and therefore not even patentable. But if somehow patentable to ISIS, they still will have 'species' claims to Wengel&#StevenQuayhttps://www.blogger.com/profile/16774112128798375734noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-39467632164081371002010-04-21T10:18:36.396+00:002010-04-21T10:18:36.396+00:00Steven,
I agree with you that regulating the stren...Steven,<br />I agree with you that regulating the strength of base pairing during RNAi (within the siRNA duplex and when bound to target mRNA) is a very important element in dealing with RNAi Therapeutics specificity. Having both UNA and BNA available in the tech tool box should certainly increase the requisite capabilities. It would be good though to see confirmation through peer-reviewed Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-21776238954990277362010-04-20T19:31:54.025+00:002010-04-20T19:31:54.025+00:00Nice post, well said.
Beyond expanding the number...Nice post, well said.<br /><br />Beyond expanding the number of druggable targets, the inherent scalability of RNAi therapeutic development is also extremely powerful. By scalability I mean, how much the investment in developing the siRNA therapeutic platform translates to the development of single drugs. Small-molecules are astonishingly non-scalable. Although we know an incredible amount Jamie Taylorhttp://www.persistentchange.comnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-60475154049309296292010-04-20T18:36:47.444+00:002010-04-20T18:36:47.444+00:00Which company has the best technology for microRNA...Which company has the best technology for microRNA mimics?Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-39061489867800082002010-04-20T17:06:56.391+00:002010-04-20T17:06:56.391+00:00Do either of you think that Santaris will be more ...Do either of you think that Santaris will be more effective at inhibiting microRNAs than Regulus?<br /><br />How does Santaris technology stack up against the blockmir technology of Mirrx Therapeutics?Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-22540144674019560152010-04-20T09:43:47.833+00:002010-04-20T09:43:47.833+00:00One more comment.
Santaris has used locked nuclei...One more comment.<br /><br />Santaris has used locked nucleic acids to form 'second generation' antisense molecules that have superior pharmacological properties to the ISIS first generation molecules. They also licensed the diagnostic uses of locked nucleic acid as superior gene probes to Exiqon which is a $200 MM plus Danish company in its own right.<br /><br />When MDRNA acquired from StevenQuayhttps://www.blogger.com/profile/16774112128798375734noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-70160135569914636952010-04-20T09:22:34.135+00:002010-04-20T09:22:34.135+00:00I got into RNAi because it was catalytic (not stoi...I got into RNAi because it was catalytic (not stoichiometric like MAb and antisense), potent (pM IC50s), and drug design 'lite' (24 hr design vs months/years/never for small molecules). First analyses comparing in vitro IC50 based on the amount of drug 'above' a cell culture with amount of drug needed to saturate the extracellular space to the same level indicated microgram/kg StevenQuayhttps://www.blogger.com/profile/16774112128798375734noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-10935968909994271892010-04-19T17:45:34.736+00:002010-04-19T17:45:34.736+00:00Thanks, Steven. I assume that it must have been a...Thanks, Steven. I assume that it must have been a similar perception of drug development trends that caused you to adopt RNAi Therapeutics as a platform.<br /><br /><br />All good questions. I invite you to browse the blog to find my opinions on some of them. As to off-target effects...it is unlikely that you will eliminate them completely, although I would expect that a profile of maybe 5 Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-78446587990755748242010-04-19T15:10:34.813+00:002010-04-19T15:10:34.813+00:00Which RNAi therapeutics technologies have the best...Which RNAi therapeutics technologies have the best chance of creating marketed drugs? Which technologies have the least amount of off-target effects? How will the off-target effects be eliminated in the future?Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-2321559139617698142010-04-19T12:17:07.318+00:002010-04-19T12:17:07.318+00:00Dirk-
Thanks for your comments of the Roche take ...Dirk-<br /><br />Thanks for your comments of the Roche take on this space.StevenQuayhttps://www.blogger.com/profile/16774112128798375734noreply@blogger.com